Back to search results

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Abroad (travel likely)RecruitingPHASE3

Conditions

Duchenne Muscular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Arkansas Children's Hospital, Little Rock, Arkansas, United States

    Contact: Study coordinator (Amber Kellogg, RN) · KelloggA@archildrens.org

  • Neurology Rare Disease Center, Flower Mound, Texas, United States

    Contact: Study coordinator (Jennifer Avelar, CRC) · Research@neuromdcenter.com

  • Children's Hospital of the King's Daughters, Norfolk, Virginia, United States

    Contact: Study coordinator (Jennifer Beachum, BSHS) · Proud.research@chkd.org

  • The Children's Hospital of Westmead, Sydney, New South Wales, Australia

    Contact: Study coordinator (CHW CRC clinical trials team) · SCHN-ClinicalTrials@health.nsw.gov.au · (02) 7825 1387
    Contact: Principal Investigator (Michelle Lorentzos, MD)

  • Alberta Children's Hospital, Calgary, Alberta, Canada

    Contact: Study coordinator (Israt Yasmeen) · Israt.Yasmeen@ahs.ca · 587-943-0851
    Contact: Principal Investigator (Jean Mah, MD)

  • BC Children's Hospital, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Nela Martic) · nmartic3@cw.bc.ca · 604-875-2345
    Contact: Principal Investigator (Kathryn Selby, MD)
View source on ClinicalTrials.gov(opens in a new tab)